Christina Mattina

Christina Mattina

Christina is the associate editorial director of The American Journal of Managed Care® (AJMC®) and Population Health, Equity & Outcomes, and joined AJMC in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.

She has a BS in public health from Rutgers University. You can connect with Christina on LinkedIn.

Articles by Christina Mattina

The 5th annual Patient-Centered Oncology Care® (PCOC) meeting, hosted by The American Journal of Managed Care, November 17-18, in Baltimore, Maryland, concluded with a panel discussion on the future of oncology care in 2017. The panelists concurred that value-based payment is here to stay despite the imminent changes in healthcare.

A study of older Americans has found that the prevalence of dementia has decreased significantly, from 11.6% in 2000 to 8.8% in 2012. It cited increased average educational attainment and improved diabetes treatments as factors that could explain the drop in dementia rates.

Federal prosecutors announced in a press conference that Gary Tanner, a former executive at Valeant Pharmaceuticals, and Andrew Davenport, former chief executive officer of Philidor Rx Services, had been charged with taking part in a multimillion-dollar fraud and kickback scheme.

President-elect Donald Trump has ignited uncertainty about the future of healthcare in America, as he has pledged to “repeal and replace” the Affordable Care Act when he enters the White House. In the meantime, bipartisan lawmakers hope to continue funding for the Precision Medicine Initiative and Cancer Moonshot by passing the 21st Century Cures legislation in the lame-duck Congress.

As the healthcare industry continues its transition towards alternative payment models (APMs), some providers might feel apprehensive about keeping up with new requirements like those in the Medicare Access and CHIP Reauthorization Act (MACRA) final rule. However, these providers can use healthcare information technology (IT), data analysis tools, and other resources to adapt to these changes, according to Suzanne Travis, vice president of regulatory strategy at McKesson.

Among the measures on the ballot for Californians this Election Day is Proposition 61, the Drug Price Standards Initiative. The measure, which would restrict the amount state agencies pay for drugs, has a multitude of supporters and opponents who have amassed a combined $125.84 million in contributions as of Monday.

In conjunction with the state of Vermont, CMS announced the Vermont All-Payer Accountable Care Organization (ACO) Model on Wednesday. The new model is the first of its kind and represents an advancement in the goal of redesigning the healthcare delivery system with an emphasis on high-value care and improved health outcomes.

The opportunities for telehealth to radically transform the healthcare system are enormous, but the foremost priority of these innovations must be the delivery of value, said Reed V. Tuckson, MD, FACP, at the National Committee for Quality Assurance Quality Talks conference in Washington, DC, on Monday.

The healthcare community needs to understand and address the personal and social circumstances that contribute to a patient’s health before they can improve the quality of care, according to 2 presentations in the first segment of the National Committee for Quality Assurance Quality Talks conference in Washington, DC.

Healthcare attorney James M. Daniel, Jr, JD, MBA, explained how healthcare providers will be impacted by CMS’ newly released final rule on the implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) in a session during the second day of the ACO & Emerging Healthcare Delivery Coalition.

HHS has issued its final rule on the Medicare Access and CHIP Reauthorization Act (MACRA), which reforms the Medicare payment system as part of the shift to value-based care. Here are 5 things to know about the final rule.

The cost of an intravenous drug used to treat lead poisoning has skyrocketed after a 2700% price increase by Valeant Pharmaceuticals. Experts worry that its high price and the lack of alternatives will place it out of reach for hospitals that need it. This is not the first time Valeant has been criticized for its price-raising practices.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo